Metastatic Uveal Melanoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Uveal Melanoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Uveal Melanoma - Pipeline Review, H2 2014', provides an overview of the Metastatic Uveal Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Uveal Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Uveal Melanoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Uveal Melanoma Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Uveal Melanoma - Overview 7
Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8
Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9
Metastatic Uveal Melanoma - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Metastatic Uveal Melanoma - Products under Development by Companies 12
Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 13
AstraZeneca PLC 13
Eli Lilly and Company 14
GlaxoSmithKline plc 15
Novartis AG 16
Spectrum Pharmaceuticals, Inc. 17
Metastatic Uveal Melanoma - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
selumetinib sulfate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
vincristine sulfate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LY-2801653 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
sotrastaurin acetate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
binimetinib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
emibetuzumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Metastatic Uveal Melanoma - Recent Pipeline Updates 44
Metastatic Uveal Melanoma - Dormant Projects 54
Metastatic Uveal Melanoma - Product Development Milestones 55
Featured News & Press Releases 55
Jun 01, 2013: AstraZeneca's New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report 55
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products under Development for Metastatic Uveal Melanoma, H2 2014 7
Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Metastatic Uveal Melanoma - Pipeline by AstraZeneca PLC, H2 2014 13
Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2014 14
Metastatic Uveal Melanoma - Pipeline by GlaxoSmithKline plc, H2 2014 15
Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2014 16
Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Assessment by Combination Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Metastatic Uveal Melanoma Therapeutics - Recent Pipeline Updates, H2 2014 44
Metastatic Uveal Melanoma - Dormant Projects, H2 2014 54